Minerva Neurosciences公司提前筹集了8 000万美元,以推进其精神分裂症药物,触发了166%的库存激增。 Minerva Neurosciences raised $80 million upfront to advance its schizophrenia drug, triggering a 166% stock surge.

Minerva Neurosciences 通过私募获得了高达 2 亿美元的资金，预先收到了 8000 万美元，用于推进罗潘立酮，这是一种治疗精神分裂症阴性症状的潜在方法。 Minerva Neurosciences secured up to $200 million in funding through a private placement, with $80 million received upfront, to advance roluperidone, a potential treatment for schizophrenia’s negative symptoms. 该公司计划将这些资金用于确认阶段3的试验,重新提出新的药物应用,并准备美国的商业发射。 The company plans to use the funds for a confirmatory Phase 3 trial, resubmit its New Drug Application, and prepare for a U.S. commercial launch. 这项交易预计于2025年10月23日左右结束,引发了166%的库存激增。 The deal, expected to close around October 23, 2025, triggered a 166% stock surge.